Guangzhou Kingmed Diagnostics Group Co., Ltd. (603882.SS)
CNY 31.24
(-1.26%)
CNY 31.24
(-1.26%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 267.61 Million CNY | -22.8% |
| 2022 | 346.63 Million CNY | -17.69% |
| 2021 | 421.12 Million CNY | 11.06% |
| 2020 | 379.18 Million CNY | 5.71% |
| 2019 | 358.69 Million CNY | -28.12% |
| 2018 | 499.02 Million CNY | -7.01% |
| 2017 | 536.62 Million CNY | 13.72% |
| 2016 | 471.87 Million CNY | 102.65% |
| 2015 | 232.85 Million CNY | 14.97% |
| 2014 | 202.53 Million CNY | 3808.1% |
| 2013 | 5.18 Million CNY | -3.0% |
| 2012 | 5.34 Million CNY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q3 | 438.81 Million CNY | 12.3% |
| 2024 Q1 | 321.27 Million CNY | 20.05% |
| 2024 Q2 | 390.74 Million CNY | 21.63% |
| 2023 Q4 | 267.61 Million CNY | -40.16% |
| 2023 FY | 267.61 Million CNY | -22.8% |
| 2023 Q1 | 325.38 Million CNY | -6.13% |
| 2023 Q2 | 362.79 Million CNY | 11.5% |
| 2023 Q3 | 447.19 Million CNY | 23.27% |
| 2022 Q3 | 317.88 Million CNY | 1.49% |
| 2022 Q2 | 313.2 Million CNY | -14.02% |
| 2022 Q1 | 364.27 Million CNY | -13.5% |
| 2022 FY | 346.63 Million CNY | -17.69% |
| 2022 Q4 | 346.63 Million CNY | 9.04% |
| 2021 Q1 | 604.82 Million CNY | 59.51% |
| 2021 Q3 | 495.59 Million CNY | 15.79% |
| 2021 Q4 | 421.12 Million CNY | -15.03% |
| 2021 FY | 421.12 Million CNY | 11.06% |
| 2021 Q2 | 428.02 Million CNY | -29.23% |
| 2020 Q4 | 379.18 Million CNY | -30.17% |
| 2020 FY | 379.18 Million CNY | 5.71% |
| 2020 Q1 | 517.08 Million CNY | 44.15% |
| 2020 Q2 | 579.2 Million CNY | 12.01% |
| 2020 Q3 | 543.04 Million CNY | -6.24% |
| 2019 FY | 358.69 Million CNY | -28.12% |
| 2019 Q4 | 358.69 Million CNY | -12.51% |
| 2019 Q3 | 410 Million CNY | 5.53% |
| 2019 Q2 | 388.51 Million CNY | -27.81% |
| 2019 Q1 | 538.16 Million CNY | 7.84% |
| 2018 Q1 | 534.39 Million CNY | -0.42% |
| 2018 Q2 | 618.88 Million CNY | 15.81% |
| 2018 FY | 499.02 Million CNY | -7.01% |
| 2018 Q3 | 658.55 Million CNY | 6.41% |
| 2018 Q4 | 499.02 Million CNY | -24.22% |
| 2017 Q3 | 570.78 Million CNY | 15.38% |
| 2017 Q1 | - CNY | -100.0% |
| 2017 FY | 536.62 Million CNY | 13.72% |
| 2017 Q2 | 494.71 Million CNY | 0.0% |
| 2017 Q4 | 536.62 Million CNY | -5.99% |
| 2016 Q4 | 471.87 Million CNY | 0.0% |
| 2016 FY | 471.87 Million CNY | 102.65% |
| 2015 Q3 | 232.73 Million CNY | 0.0% |
| 2015 FY | 232.85 Million CNY | 14.97% |
| 2015 Q4 | 232.85 Million CNY | 0.05% |
| 2014 FY | 202.53 Million CNY | 3808.1% |
| 2013 FY | 5.18 Million CNY | -3.0% |
| 2012 FY | 5.34 Million CNY | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Shanghai Runda Medical Technology Co., Ltd. | 1.1 Billion CNY | 75.729% |
| Joinn Laboratories(China)Co.,Ltd. | 41.92 Million CNY | -538.319% |
| WuXi AppTec Co., Ltd. | 687.01 Million CNY | 61.047% |
| Autobio Diagnostics Co., Ltd. | 24.63 Million CNY | -986.28% |
| Thalys Medical Technology Group Inc. | 596.75 Million CNY | 55.155% |
| Chemclin Diagnostics Co., Ltd. | 227.94 Million CNY | -17.4% |